Elan sells Prialt to ex-execs' firm Azur
This article was originally published in Scrip
Executive Summary
Elan is to sell the rights to its pain infusion drug Prialt (ziconotide) to Azur Pharma, a company set up by former executives of the Irish pharmaceutical group in 2005. Dublin, Ireland-based Azur will acquire all rights globally except for Europe, which were acquired by Eisai in 2006.